Peptide Dosing Frequency Research Guide 2026 — How Half-Life Shapes Protocol Design

Every research protocol's dosing frequency decision should start from the compound's half-life and work backward to the desired receptor occupancy pattern — not from convention or community practice. Understanding this relationship is what separates rigorous research design from guesswork.

The Half-Life to Frequency Relationship

A compound with a 10-minute half-life administered once daily produces a brief peak followed by near-complete clearance — essentially a single pulsatile event with 23+ hours of no receptor engagement. The same compound administered three times daily produces three separated pulses with partial recovery between them. As explored in our half-life guide, these are fundamentally different research designs even though they use the same compound at equivalent total daily exposure.

Pulsatile vs Continuous Research Designs

GH-axis research is where this distinction matters most. Short-acting secretagogues like Sermorelin and Ipamorelin produce pulsatile GH release mimicking physiologic patterns when dosed once or twice daily — the receptor sees a stimulation followed by clearance followed by another stimulation. CJC-1295 with DAC produces continuous GHRH receptor occupancy that maintains sustained low-level GH elevation — a "GH bleed" effect as described in our CJC-1295 expanded guide. Both are valid research designs but they answer different questions about GH receptor biology.

Dosing Patterns Across Major Research Categories

GLP-class compounds like Semaglutide and Tirzepatide are designed for once-weekly administration due to their engineered half-lives. Recovery peptides like BPC-157 and TB-500 are typically studied once or twice daily given their shorter half-lives. Longevity compounds like Epithalon are sometimes studied in periodic cycles — on-protocol followed by off-protocol — based on the research hypothesis that episodic telomerase activation may be sufficient rather than continuous stimulation.

Using Ares One to Track Complex Dosing Schedules

The Ares One app manages different dosing frequencies across multiple concurrent compounds without the researcher needing to manually track which compound is due when — setting each protocol's schedule independently and surfacing everything due each day through the unified dashboard.

Related Research Peptide Half-Life Guide 2026 HGH Pulsatile Release Research CJC-1295 DAC vs Non-DAC Guide Tracking Peptide Stacks in Ares One

Research Use Only. DisclaimerFor laboratory and research use only. Not for human consumption. This content is educational and does not constitute medical advice.